Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT
Standard
Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT. / Heidenreich, Silke; Ziagkos, Dimitris; de Wreede, Liesbeth C; van Biezen, Anja; Finke, Jürgen; Platzbecker, Uwe; Niederwieser, Dietger; Einsele, Hermann; Bethge, Wolfgang; Schleuning, Michael; Beelen, Dietrich W; Tischer, Johanna; Nagler, Arnon; Glass, Bertram; Maertens, Johan; Yáñez, Lucrecia; Beguin, Yves; Sill, Heinz; Scheid, Christof; Stelljes, Matthias; Ganser, Arnold; Zachée, Pierre; Selleslag, Dominik; de Witte, Theo; Robin, Marie; Kröger, Nicolaus.
In: BIOL BLOOD MARROW TR, Vol. 23, No. 1, 01.2017, p. 44-52.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT
AU - Heidenreich, Silke
AU - Ziagkos, Dimitris
AU - de Wreede, Liesbeth C
AU - van Biezen, Anja
AU - Finke, Jürgen
AU - Platzbecker, Uwe
AU - Niederwieser, Dietger
AU - Einsele, Hermann
AU - Bethge, Wolfgang
AU - Schleuning, Michael
AU - Beelen, Dietrich W
AU - Tischer, Johanna
AU - Nagler, Arnon
AU - Glass, Bertram
AU - Maertens, Johan
AU - Yáñez, Lucrecia
AU - Beguin, Yves
AU - Sill, Heinz
AU - Scheid, Christof
AU - Stelljes, Matthias
AU - Ganser, Arnold
AU - Zachée, Pierre
AU - Selleslag, Dominik
AU - de Witte, Theo
AU - Robin, Marie
AU - Kröger, Nicolaus
N1 - Copyright © 2016 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
PY - 2017/1
Y1 - 2017/1
N2 - In this retrospective analysis we evaluated the outcome of 313 patients aged ≥ 70 years in the registry of the European Group for Blood and Marrow Transplantation with myelodysplastic syndrome (MDS; n = 221) and secondary acute myeloid leukemia (n = 92) who underwent allogeneic hematopoietic stem cell transplantation (HSCT) from related (n = 79) or unrelated (n = 234) donors. Median age at HSCT was 72 years (range, 70 to 78). Conditioning regimen was nonmyeloablative (n = 54), reduced intensity (n = 207), or standard intensity (n = 52). Allogeneic HSCT for MDS patients ≥ 70 years was increasingly performed over time. Although during 2000 to 2004 only 16 patients received HSCT, during 2011 to 2013 the number of transplantations increased to 181. The cumulative incidence of nonrelapse mortality at 1 year and relapse at 3 years was 32% and 28%, respectively, with a 3-year overall survival rate of 34%. Good performance, determined by Karnofsky performance status, and recipients' seronegativity for cytomegalovirus was associated with 3-year estimated overall survival rates of 43% (P = .01) and 46% (P = .002), respectively. Conditioning intensity did not impact survival. After careful patient selection, allogeneic HSCT can be offered to patients older than 70 years with MDS.
AB - In this retrospective analysis we evaluated the outcome of 313 patients aged ≥ 70 years in the registry of the European Group for Blood and Marrow Transplantation with myelodysplastic syndrome (MDS; n = 221) and secondary acute myeloid leukemia (n = 92) who underwent allogeneic hematopoietic stem cell transplantation (HSCT) from related (n = 79) or unrelated (n = 234) donors. Median age at HSCT was 72 years (range, 70 to 78). Conditioning regimen was nonmyeloablative (n = 54), reduced intensity (n = 207), or standard intensity (n = 52). Allogeneic HSCT for MDS patients ≥ 70 years was increasingly performed over time. Although during 2000 to 2004 only 16 patients received HSCT, during 2011 to 2013 the number of transplantations increased to 181. The cumulative incidence of nonrelapse mortality at 1 year and relapse at 3 years was 32% and 28%, respectively, with a 3-year overall survival rate of 34%. Good performance, determined by Karnofsky performance status, and recipients' seronegativity for cytomegalovirus was associated with 3-year estimated overall survival rates of 43% (P = .01) and 46% (P = .002), respectively. Conditioning intensity did not impact survival. After careful patient selection, allogeneic HSCT can be offered to patients older than 70 years with MDS.
U2 - 10.1016/j.bbmt.2016.09.027
DO - 10.1016/j.bbmt.2016.09.027
M3 - SCORING: Journal article
C2 - 27720995
VL - 23
SP - 44
EP - 52
JO - BIOL BLOOD MARROW TR
JF - BIOL BLOOD MARROW TR
SN - 1083-8791
IS - 1
ER -